U.S. Preclinical Cro Market Size & Outlook, 2026-2033
Related Markets
U.S. preclinical cro market highlights
- The U.S. preclinical cro market generated a revenue of USD 1,666.8 million in 2025 and is expected to reach USD 3,066.5 million by 2033.
- The U.S. market is expected to grow at a CAGR of 7.7% from 2026 to 2033.
- In terms of segment, preclinical optimization, efficacy & pk/pd was the largest revenue generating development stage in 2025.
- Early CMC / Phase I–II Supply is the most lucrative development stage segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2025 | USD 1,666.8 million |
| Market revenue in 2033 | USD 3,066.5 million |
| Growth rate | 7.7% (CAGR from 2026 to 2033) |
| Largest segment | Preclinical optimization, efficacy & pk/pd |
| Fastest growing segment | Early CMC / Phase I–II Supply |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Target Discovery, Preclinical Optimization, Efficacy & PK/PD, IND-Enabling Safety (GLP), Bioanalysis & Analytics, Early CMC / Phase I–II Supply |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, U.S. accounted for 24.9% of the global preclinical cro market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. preclinical cro market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,886.7 million by 2033.
Preclinical optimization, efficacy & pk/pd was the largest segment with a revenue share of 34.43% in 2025. Horizon Databook has segmented the U.S. preclinical cro market based on target discovery, preclinical optimization, efficacy & pk/pd, ind-enabling safety (glp), bioanalysis & analytics, early cmc / phase i–ii supply covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. accounts for the highest share in the global preclinical trial outsourcing market as a large number of pharmaceutical and life sciences companies are present in this region. CROs in the country possess various capabilities such as genotoxicity and immunotoxicity testing services, which are majorly carried out in the U.S. Along with this, rapid growth in emerging areas of medicine such as personalized medicines, orphan drugs, and biosimilar is expected to propel growth of the preclinical trial outsourcing market in the U.S.
A significant proportion of R&D expenditure by pharmaceutical and life sciences companies are allotted to preclinical trials. Adherence to safety protocols is ensured during the preclinical trials phase before undertaking further stages of drug development.
In addition, failure rate of preclinical trials is significantly lower than failures in further stages. Significant investments were made for preclinical studies by the pharmaceutical companies in recent years.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| SGA | View profile | 11-50 | Las Condes, Region Metropolitana, Chile, South America | https://sgasa.cl |
| Crown Bioscience | View profile | 251-500 | Santa Clara, California, United States, North America | http://www.crownbio.com |
| Intertek Group PLC | View profile | 44000 | 33 Cavendish Square, London, United Kingdom, W1G 0PS | https://www.intertek.com |
| Medpace Holdings Inc | View profile | 5800 | 5375 Medpace Way, Cincinnati, OH, United States, 45227 | https://www.medpace.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
US Development Stage - Preclinical Cro Market size, 2025 - 2033 (US$M)
U.S. Preclinical CRO Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
